fda
24 records
FDA Drug Recall: Lidocaine-phenylephrine 1%-1.5% 1mL Single Dose Vial, Rx only, Compounded by Pin
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Cefuroxime 4mg /0.4 mL (10 mg/mL), 1mL syringe, Rx only, Compounded by: Pine Pha
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Moxifloxacin in Balanced Salt Solution 400 mcg/0.4 mL (100 mcg/0.1 mL) 1 mL syri
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Calcium chloride Solution for Intravenous Injection, 20 mg/mL, 500 mL bags, Rx o
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Lidocaine HCl 4% ophthalmic solution, 3 mL single-use dropper, Rx only, Compound
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Moxifloxacin in Balanced Salt Solution, Solution for Intraocular Injection, 600
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: TPC Drops (tropicamide 1%- phenylephrine 2.5%- cyclopentolate HCl 1% ophthalmic
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Calcium Gluconate Ophthalmic Irrigation Solution 1%, 500 mL bags, Rx only, Comp
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Lidocaine HCL 2% and Oxymetazoline HCl 0.025% Solution for intranasal administra
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Calcium Gluconate 2.5% solution for inhalation, 5mL pre-filled syringes, Rx only
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Vancomycin 1 MG/0.1 ML Solution for Intraocular Injection, 0.8 ML Single Dose Vi
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Tropi-Phen (tropicamide 1%, phenylephrine 2.5%) ophthalmic solution, 5mL multi-u
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Bevacizumab 1.25 MG/0.05 ML Solution for Injection, 1 mL syringes, Rx only, Comp
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Endophth Kit (Vancomycin 1mg/0.1 mL - Ceftazidime 2.25mg/0.1 mL), Rx only, Compo
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Foscarnet Sodium 2.4mg/0.1 mL solution for injection, 0.2 mL single-dose Stacle
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Tropi-Phen (Tropicamide 1% phenylephrine HCl 2.5%) ophthalmic solution, 15 mL mu
2023-10-25
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Bevacizumab 2.5 mg/0.1 mL, Solution for Injection in 1mL, silicone free slip tip
2023-04-19
Class III — Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.
View Source
FDA Drug Recall: Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injec
2023-01-11
Class II — CGMP Deviations: Raw material recalled by repackager, due to discoloration.
View Source
FDA Drug Recall: Bupivacaine HCl 0.375% w/v and Lidocaine HCl 2% w/v Solution for Retrobulbar or
2022-09-21
Class II — Lack of Assurance of Sterility
View Source
FDA Drug Recall: Brilliant Blue G for Intraocular Injection 0.5mL vial 0.25 mg/mL Compounded by:
2018-03-28
Class III — Labeling: Label Mix-Up: Brilliant Blue G was labeled with an inaccurate auxiliary label which contained active/inactive ingredient information for incorrect product.
View Source
FDA Drug Recall: Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal Rx --
2016-01-27
Class II — Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
View Source
FDA Drug Recall: Bevacizumab 2 mg/0.08 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal, Rx -- P
2016-01-27
Class II — Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
View Source
FDA Drug Recall: Bevacizumab 2.5 mg/0.1 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal injecti
2016-01-27
Class II — Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
View Source
FDA Drug Recall: Bevacizumab 1.25 mg/0.05 mL filled to 0.06 mL in 3/10 mL 31 G 5/16" Syringe for
2016-01-27
Class II — Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
View Source
nppes
1 records
ny_corps
1 records
NY Corp: PINE PHARMACEUTICALS LLC
2014-02-28
DOMESTIC LIMITED LIABILITY COMPANY | County: Erie | Jurisdiction: New York
View Source
Be informed when major changes happen on C.F.A.I. — new data sources, platform updates, critical enforcement alerts
No spam. Only major updates. Unsubscribe anytime.